Search Within

Sarcoma Service

Formats
  1. Journal Article (455)
  2. Meeting Abstract (431)
  3. Review (29)
  4. Editorial (9)
  5. Guidelines (8)
  6. Book Section (6)
  7. Miscellaneous (6)
  8. Research Letter (6)
  9. Correspondence (2)
  10. Book Whole (1)
Groups
  1. Department of Medicine (953)
  2. Solid Tumor Oncology Division (953)
  3. GSK Faculty (343)
  4. Tow Center for Developmental Oncology (TCDO) (310)
  5. Hematologic Malignancies, Division of (295)
  6. Department of Pathology and Laboratory Medicine (241)

More Groups

People
  1. William Tap (382)
  2. Sandra D'Angelo (256)
  3. Mrinal Gounder (232)
  4. Ping Chi (177)
  5. Mark Dickson (173)
  6. Cristina Antonescu (138)

More People

Years
  1. 2025 (44)
  2. 2024 (87)
  3. 2023 (79)
  4. 2022 (116)
  5. 2021 (76)
  6. 2020 (90)

More Years

Publications
  1. Journal of Clinical Oncology (274)
  2. Annals of Oncology (70)
  3. Clinical Cancer Research (61)
  4. Cancer Research (31)
  5. Journal for ImmunoTherapy of Cancer (28)
  6. Cancer (19)

More Publications

Publishers
  1. American Society of Clinical Oncology (288)
  2. American Association for Cancer Research (108)
  3. Oxford University Press (92)
  4. Elsevier Inc. (57)
  5. Nature Publishing Group (42)
  6. Springer (40)

More Publishers

Results (953)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • ADAM Trial: A multicenter, randomized, double-blinded, placebo-controlled, phase 3 trial of adjuvant avelumab (anti-PD-L1 antibody) in Merkel cell carcinoma patients with lymph node metastases; NCT03271372
    Meeting Abstract

    Chen, W.; Bhatia, S.; Brohl, A. S.; Chandra, S.; Dakhil, S.; Fecher, L. A.; Gao, L.; Gooley, T. A.; Hanna, G. J.; Hibbert, R.; more...
    Journal of Investigative Dermatology (2022)

    Fulltext@MSK | Save
  • Navtemadlin (KRT-232) in combination with avelumab for patients with anti-PD-1/L1 treatment-naïve TP53(WT) Merkel cell carcinoma (MCC)
    Meeting Abstract

    Wong, M. K.; Burgess, M.; Chandra, S.; Schadendorf, D.; Silk, A.; Olszanski, A. J.; Grob, J. J.; Jang, S.; Grewal, J. S.; Lewis, K. D.; more...
    Journal of Investigative Dermatology (2022)

    Fulltext@MSK | Save
  • DeFi: A phase III, randomized controlled trial of nirogacestat versus placebo for progressing desmoid tumors (DT)
    Meeting Abstract

    Kasper, B.; Ratan, R.; Alcindor, T.; Schoeffski, P.; van Der Graaf, W. T. A.; Wilky, B. A.; Riedel, R. F.; Lim, A.; Smith, L. M.; Moody, S.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Initial results of phase II/III trial of AL102 for treatment of desmoid tumors (DT)
    Meeting Abstract

    Gounder, M. M.; Jones, R. L.; Chugh, R.; Agulnik, M.; Singh, A.; Van Tine, B. A.; Andelkovic, V.; Choy, E.; Lewin, J.; Ratan, R.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Efficacy and safety of vimseltinib in tenosynovial giant cell tumour (TGCT): Phase II expansion
    Meeting Abstract

    Blay, J. Y.; Gelderblom, H.; Rutkowski, P.; Wagner, A.; van de Sande, M.; Gonzalez, A. F.; Stacchiotti, S.; Le Cesne, A.; Alcindor, T.; Serrano, C.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Safety and efficacy of vimseltinib in tenosynovial giant cell tumour (TGCT): Long-term phase I update
    Meeting Abstract

    Gelderblom, H.; Abdul Razak, A.; Martin-Broto, J.; Wilky, B. A.; Rutkowski, P.; Narasimhan, S.; Vallee, M.; Sharma, M.; Ruiz-Soto, R.; Sherman, M. L.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • A phase I dose-escalation and expansion study evaluating the safety and efficacy of the MDM2-p53 antagonist BI 907828 in patients (pts) with solid tumours
    Meeting Abstract

    Schoeffski, P.; Yamamoto, N.; Bauer, T.; Patel, M.; Gounder, M. M.; Geng, J.; Sailer, R.; Jayadeva, G.; Lorusso, P.
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • METEOR-1: A phase I study of the safety and efficacy of the protein arginine methyltransferase 5 (PRMT5) inhibitor GSK3326595 in advanced solid tumors
    Meeting Abstract

    Postel-Vinay, S.; Italiano, A.; Martin Romano, P.; Cassier, P. A.; Siu, L. L.; Lossos, I. S.; Hilton, J. F.; Mckean, M. A.; Strauss, J.; Falchook, G. S.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Identifying participants’ preferences for modifiable chemotherapy-induced peripheral neuropathy prevention clinical trial factors: An adaptive choice-based conjoint analysis
    Journal Article

    Knoerl, R.; Berry, D.; Meyerhardt, J. A.; Reyes, K.; Salehi, E.; Thornton, K.; Gewandter, J. S.
    Supportive Care in Cancer (2022)

    Fulltext@MSK | Save
  • The genetic landscape of SMARCB1 alterations in SMARCB1-deficient spectrum of mesenchymal neoplasms
    Journal Article

    Dermawan, J. K.; Singer, S.; Tap, W. D.; Nacev, B. A.; Chi, P.; Wexler, L. H.; Ortiz, M. V.; Gounder, M.; Antonescu, C. R.
    Modern Pathology (2022)

    Fulltext@MSK | Save